D-0714-2026 Class II Ongoing
FDA drug recall D-0714-2026 was initiated by McKesson on Jun 10, 2026 and is designated Class II. Reason for recall: Temperature Abuse: Product was stored incorrectly in a controlled room temperature environment instead of a refrigerated environment. The recall status is ongoing. Affected quantity: 74 units.
Recall details
- Product Type
- Drugs
- Report Date
- Jul 8, 2026
- Initiation Date
- Jun 10, 2026
- Voluntary/Mandated
- Voluntary: Firm initiated
- Product Quantity
- 74 units
Product description
Gemcitabine Injection, 1 g per 26.3 mL (38 mg/mL), 26.3 mL Single-Dose Vial, For Intravenous Infusion ONLY, Rx only, Manufactured by: THYMOORGAN PHARMAZIE GmbH, Schiffgraben 23, 38690 Goslar, Germany; Distributed by: Hikma, Berkeley Heights, NJ 07922. NDC: 0143-9341-01
Reason for recall
Temperature Abuse: Product was stored incorrectly in a controlled room temperature environment instead of a refrigerated environment.
Distribution pattern
Nationwide within the United States
Code information
Lot #: CB0046, Exp. Date 06/2027
Source
- Dataset
- openFDA drug recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for D-0714-2026
- openFDA file date
- Nov 10, 2026
- Loaded by RegDataLab
- Nov 11, 2026